Is Alnylam Pharmaceuticals stock a buy or sell?
Alnylam Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 35 buy ratings, 13 hold ratings, and 0 sell ratings. What was the 52-week low for Alnylam Pharmaceuticals stock? The low in the last 52 weeks of Alnylam Pharmaceuticals stock was 117.62.
Where can I buy ALNY shares?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Why is Alnylam valued at six-figure pricing?
Alnylam's valuation rests on its ability to maintain six-figure pricing and payers' willingness to continue reimbursement, which could be affected by shifts in healthcare drug policy.
Who is the founder of Alnylam?
The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. Alnylam Pharmaceuticals has received a consensus rating of Buy.
Is Alny stock a buy?
Alnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 13 buy ratings, 5 hold ratings, and no sell ratings.
Why is Alny stock dropping?
The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the quarter. The company also announced its CEO, John Maraganore, will be retiring at the end of 2021.
Is Alnylam a takeover target?
Could one of her first major acts be leading the RNAi specialist to a takeover? It's been less than a month since Greenstreet, previously president and COO, took the reins from John Maraganore, Ph. D., and Alnylam has already been singled out as a top M&A target for the year.
Is Alnylam publicly traded?
When did Alnylam go public? Alnylam started trading publicly in May 2004.
Is ALNY stock a buy right now?
18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 3...
Will Alnylam Pharmaceuticals' stock price go up in 2022?
18 Wall Street analysts have issued twelve-month target prices for Alnylam Pharmaceuticals' stock. Their forecasts range from $103.00 to $430.00. O...
How has Alnylam Pharmaceuticals' stock performed in 2022?
Alnylam Pharmaceuticals' stock was trading at $169.58 at the start of the year. Since then, ALNY shares have decreased by 20.4% and is now trading...
When is Alnylam Pharmaceuticals' next earnings date?
Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast f...
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings data on Thursday, April, 28th. The biopharmaceutical company reported ($2...
What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?
Alnylam Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the peri...
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the following people: Mr. Michael W. Bonney B.A. , Exec. Chairman (Age 64, Pay $317.97k) Dr. Y...
What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?
65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com . John M. Maraganore has an approval rating of 99% among A...
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...
When will Alnylam release its earnings?
How much does Alnylam make?
Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021. View our earnings forecast for Alnylam Pharmaceuticals.
Nasdaq Global Select
How much money does Alnylam Pharmaceuticals make? Alnylam Pharmaceuticals has a market capitalization of $20.76 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858,280,000.00 in net income (profit) each year or ($7.46) on an earnings per share basis.
Environmental, Social, and Governance Rating
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
